Silymarin does not affect virus activity or ALT levels in

In a survey of patients with chronic hepatitis C who participated in a National Institute of Diabetes and Digestive and Kidney Diseases-sponsored long-term treatment trial for patients who had failed to respond previously to antiviral therapy, approximately 40% acknowledged to interviewers at the ...

New upper limit defined for normal ALT in adolescent males

A new cohort study of adolescent offenders in Australia has identified an upper limit for ALT that is more sensitive for the diagnosis of liver disease. The findings could facilitate targeted interventions for the youths in this group, who are at high risk for HCV infection and obesity-related liv...

Grocery Manufacturers Association Releases Science Policy Paper on Sodium and Salt

The Grocery Manufacturers Association (GMA) today released Sodium and Salt: A Guide for Consumers, Policymakers and the Media, a science policy paper that provides current and scientifically accurate information and resources on sodium and salt. Washington, DC (PRWEB) J...

Hypertension can be caused by Inhalation of Salt

Eating more salt causes high blood pressure is well known, however// a new study reports that even inhaling salt can cause it. A study published today in the Open Access journal Environmental Health for the first time has shown that breathing in large quantities of salt particles can have just...

AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease

... models of acute liver injury. Very high levels of alt are usually due to acute hepatitis or a viral infe...as model of liver injury, GAI-122 markedly reduced alt levels by 90% from baseline, where control alt values were ~22,000 IU/L. Significant efficacy was...

Environmental pollution increases the risk of liver disease

...e specific pollutants included were detectable in 60 percent or more of the 4,500 study subjects. Dr. Cave added that this analysis used only the alt liver enzyme as a marker of liver injury, and cautioned that this associative study does not prove causality. However, he added that previous animal ...

Guidelines Enhance Safety for Bariatric Surgery Patients

...tin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA . 2006;295:1549-1555. (2) alt SJ. Bariatric surgery programs growing quickly nationwide. Health Care Strateg Manage . 2001;19:7-23. Greenway FL. Surgery for obesity. Endocri...

Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal

...st common adverse event with Pennsaid use. Fewer digestive system adverse events and laboratory abnormalities (decreased hemoglobin and increased AST, alt and creatinine) were observed with Pennsaid as compared to oral diclofenac. About Nuvo Research Inc. Nuvo is focused on the research and dev...

NuVasive Reports First Quarter 2009 Financial Results

...e the transa c tion in the ex pe c ted tim e frame or that int e r ve ning factors may c ause the parties to alt e r the ter m s ( finan c ial or otherwis e ) of the transa c tion; t h e risk that NuVasive ...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)

... in patients with a history of a seizure disorder, mania or controlled narrow-angle glaucoma. Savella has been associated with mild elevations of alt and AST. Rarely, fulminant hepatitis has been reported in patients treated with milnacipran. Savella should be discontinued in patients who develop ja...

More>>

ALT in Medical Technology

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...ncrease in Blood Pressure (BP) 1 1% 7 5% ------------------------------- --- --- --- --- alt or Alkphos Elevation 0 0% 4 3% ------------------------ --- --- --- --- ...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

..." In the 75 and 100 mg/day cohorts, patients receiving IDX184 experienced improvements in two key markers of liver injury, with mean AST and alt levels decreasing to below the upper limit of normal. These improvements were sustained for up to 6 days post-dosing, and most levels returned to base...

Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome

...d pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels indicative of liver damage, such as alt and AST, are decreased, pointing to an outstanding safety profile. Increases in HDL, the "good" cholesterol and increased insulin sensitivity have als...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...s 1 1% 5 3% 9 6% Increase in Blood Pressure 2 1% 4 3% 6 4% alt or Alkphos Elevation 2 1% 6 4% 5 3% Treatment Emergent Adverse Events ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

...sts, Grade 3/4 abnormalities were noted slightly more frequently in patients treated with pirfenidone (phosphate elevation, hyponatremia, lymphopenia, alt elevation, AST elevation and cholesterol elevation). Of these laboratory abnormalities in pirfenidone patients, all but one case each of hyponatremia...

CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis

...t 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in alt or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who cons...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

...t 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in alt or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who cons...

Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)

... to the following statements: Raptor's and UC San Diego's ability to complete the clinical trial in NASH patients, cysteamine's ability to treat NASH, alt and AST as a biomarker to determine the efficacy of a treatment for NASH, Raptor's ability to further develop cysteamine in NASH and other indications...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

... Patients receiving therapy with PROMACTA must have regular monitoring of serum liver tests (see Laboratory Monitoring below). Discontinue PROMACTA if alt levels increase to greater than or equal to 3X upper limit of normal (ULN) and are: progressive; or persistent for greater than or equal to 4 weeks, o...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

...s receiving therapy with PROMACTA must have regular monitoring of serum liver tests (see Laboratory Monitoring below). Discontinue PROMACTA if alt levels increase to > / = 3X upper limit of normal (ULN) and are: progressive; or persistent for > / = 4 weeks, or; accompanied by increased di...

More>>